Ludin H P
Neurological Clinic, University of Berne, Switzerland.
Eur Neurol. 1987;27 Suppl 1:73-5. doi: 10.1159/000116196.
Eleven patients suffering from idiopathic Parkinson's disease participated in an open study of Madopar HBS. At the beginning the patients were switched from standard Madopar to Madopar HBS, initially keeping constant L-dopa dosage and the number of daily doses. In 9 of the 11 patients a marked deterioration occurred within a few days. In spite of increasing the daily dosage of L-dopa the condition remained unsatisfactory in several patients and forced us to prematurely discontinue the study in 5 cases. The Webster ratings improved in 1 patient, remained unchanged in 4 cases and a definite worsening occurred in 6 patients. Fluctuations of the symptomatology were improved in none of our patients. It is not excluded that these negative results might have been improved by a further increase of Madopar HBS, a less abrupt switch from standard Madopar to Madopar HBS and probably also a combination of the two forms.
11名特发性帕金森病患者参与了美多芭HBS的一项开放性研究。开始时，患者从标准美多芭转换为美多芭HBS，最初保持左旋多巴剂量和每日服药次数不变。11名患者中有9名在几天内出现明显恶化。尽管增加了左旋多巴的每日剂量，但仍有几名患者的病情不尽人意，迫使我们在5例患者中提前终止研究。1名患者的韦伯斯特评分改善，4例不变，6例明显恶化。我们的患者中症状波动均未改善。不排除通过进一步增加美多芭HBS剂量、从标准美多芭向美多芭HBS的转换不那么突然以及可能将两种剂型联合使用，这些负面结果可能会得到改善。
